Fairvalue-Calculator Fairvalue-Calculator
EN DE

Apellis Pharmaceuticals, Inc (APLS) Fair Value & Analysis

Healthcare · US · Market cap $5.3B

Price$3.51
Fair Value$0.4700
Upside-86.6%
Quality95/100
Evidence: High Range $0.3200 – $0.6100

Fair value as of: Jun 24, 2026

Analysis

Apellis Pharmaceuticals, Inc (APLS) currently trades at $3.51, while our model-based Fair Value estimate is $0.4700 — implying the stock looks roughly 86.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam c…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Apellis Pharmaceuticals, Inc (APLS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.4700 versus a price of $3.51 — about −87% (overvalued). Model-based estimate, not financial advice.
What is the fair value of APLS?
Our 21-model fair value for Apellis Pharmaceuticals, Inc is $0.4700 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.51.
What is the quality score of APLS?
Apellis Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.